Results 241 to 250 of about 38,538 (308)

2026 Update on the Management of Diffuse Large B-Cell Lymphoma. [PDF]

Am J Hematol
Chong EA, Tomasulo EB, Barta SK.
europepmc   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, Volume 53, Issue 5, Page 422-426, May 2026.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source

Dendritic Cell-T Cell Crosstalk Mediated Cancer Immunotherapy. [PDF]

Exploration (Beijing)
Cai Y, Chen J, Li Y.
europepmc   +1 more source

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

European Journal of Haematology, Volume 116, Issue 5, Page 577-584, May 2026.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma, Eshetu G. Atenafu, Esther Masih‐Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A. Keith Stewart, Rodger Tiedemann, Suzanne Trudel, Chloe Yang, Donna Reece   +13 more
wiley   +1 more source

Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report. [PDF]

Case Rep Oncol
Uemura Y, Togitani K, Nakashima J.
europepmc   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, Volume 116, Issue 5, Page 522-534, May 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies. [PDF]

Front Immunol
Álvarez-Vallina L, Sanz L.
europepmc   +1 more source

Defining the tumor microenvironment of non‐small cell lung cancer

Immunology &Cell Biology, Volume 104, Issue 5, Page 499-518, May‐June 2026.
The tumor microenvironment (TME) in non‐small cell lung cancer is highly heterogeneous, both at a patient level and tumor microenvironment resolution. Defining the tumor microenvironment from patient‐responders and non‐responders will aid in the development of targeted therapeutics specific for each individual patient.
Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G. M. Hughes, Arutha Kulasinghe   +5 more
wiley   +1 more source

CAR-T and BiTE: new horizons in the treatment of rheumatic autoimmune diseases. [PDF]

Front Immunol
Li J, Guo Q, Li L, Wang J, Zhang L.
europepmc   +1 more source